DMET Plus Product offers 1,936 biomarkers for drug response and transport.

The Coriell Personalized Medicine Collaborative (CPMC) selected Affymetrix’ DMET Plus Product for a national project to identify biologically relevant markers for drug response. The CPMC plans to enroll 10,000 individuals by the end of 2009 with an ultimate goal of 100,000.

The DMET Plus Product has a panel that includes markers in all FDA-validated genes and covers more than 90% of the current ADME Core markers as defined by the PharmaADME group. In total, the DMET Plus Product offers 1,936 drug metabolism and transport markers.

Launched in December 2007, the CPMC has been using the Genome-Wide Human SNP Array 6.0 to identify genes associated with health conditions such as cancer, heart and blood vessel diseases, and diabetes. With the DMET Plus Product, the CPMC will expand these investigations to include direct interrogation of markers for drug metabolism and transport to build a database of genetic information related to drug response.

“Without the DMET Plus Product we would have been confined to an ad hoc, one-off assay, which limits us to the narrowest set of biomarkers,” points out Michael F. Christman, Ph.D., president and CEO, the Coriell Institute for Medical Research. “In addition, some drug metabolism markers are highly challenging technically and the DMET Plus Product offers us the best chance of measuring them.”

Since the DMET Plus Product was launched last November, Affymetrix says that five additional organizations have adopted it to support studies investigating the relationship between genes and drug metabolism and 18 are scheduled to be trained.


Previous articleJ.P. Morgan Healthcare Conference—Monday, January 12 Update
Next articleInvestigators Use DNA Repair Patterns to Determine Pancreatic Cancer Risk